Free Trial
NASDAQ:KPTI

Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis

Karyopharm Therapeutics logo
$3.86 0.00 (0.00%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$3.95 +0.09 (+2.33%)
As of 04/4/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Karyopharm Therapeutics Stock (NASDAQ:KPTI)

Key Stats

Today's Range
$3.51
$3.89
50-Day Range
$3.54
$10.29
52-Week Range
$3.51
$21.30
Volume
143,600 shs
Average Volume
80,747 shs
Market Capitalization
$32.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.50
Consensus Rating
Buy

Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Remove Ads

Karyopharm Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

KPTI MarketRank™: 

Karyopharm Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 311th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Karyopharm Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Karyopharm Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Karyopharm Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.43) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Karyopharm Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Karyopharm Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Karyopharm Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.63% of the float of Karyopharm Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Karyopharm Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Karyopharm Therapeutics has recently increased by 0.94%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Karyopharm Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Karyopharm Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.63% of the float of Karyopharm Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Karyopharm Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Karyopharm Therapeutics has recently increased by 0.94%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Karyopharm Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Karyopharm Therapeutics this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    Only 2 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Karyopharm Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.75% of the stock of Karyopharm Therapeutics is held by insiders.

  • Percentage Held by Institutions

    66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Karyopharm Therapeutics' insider trading history.
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Stock News Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Karyopharm Therapeutics (KPTI) Receives a Buy from Piper Sandler
Karyopharm price target lowered to $54 from $75 at Baird
See More Headlines

KPTI Stock Analysis - Frequently Asked Questions

Karyopharm Therapeutics' stock was trading at $10.1445 on January 1st, 2025. Since then, KPTI stock has decreased by 61.9% and is now trading at $3.86.
View the best growth stocks for 2025 here
.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its quarterly earnings results on Wednesday, February, 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts' consensus estimates of ($3.90) by $0.30. The firm earned $30.54 million during the quarter, compared to analyst estimates of $30.29 million.

Karyopharm Therapeutics shares reverse split before market open on Wednesday, February 26th 2025. The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Enovix (ENVX), Tesla (TSLA), Globant (GLOB), Luminar Technologies (LAZR) and Rambus (RMBS).

Company Calendar

Last Earnings
2/19/2025
Today
4/05/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KPTI
Fax
N/A
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$57.50
High Stock Price Target
$75.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+1,389.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-143,100,000.00
Pretax Margin
-52.58%

Debt

Sales & Book Value

Annual Sales
$145.24 million
Price / Cash Flow
N/A
Book Value
($1.47) per share
Price / Book
-2.63

Miscellaneous

Free Float
122,721,000
Market Cap
$32.49 million
Optionable
Optionable
Beta
0.11

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:KPTI) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners